PMC:7274950 / 96-1497
Annnotations
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T2 | 20-21 | GO:0000805 | denotes | X |
T3 | 64-73 | GO:0005764 | denotes | lysosomal |
T4 | 254-261 | UBERON:0000948 | denotes | cardiac |
T5 | 263-271 | UBERON:0001893 | denotes | cerebral |
T6 | 276-281 | UBERON:0002113 | denotes | renal |
T7 | 309-318 | UBERON:0002048 | denotes | pulmonary |
T8 | 387-391 | UBERON:0002048 | denotes | lung |
T9 | 450-461 | NCBITaxon:11118 | denotes | Coronavirus |
T10 | 474-482 | SP_7 | denotes | COVID-19 |
T11 | 499-509 | SP_7 | denotes | SARS-CoV-2 |
T12 | 510-515 | NCBITaxon:10239 | denotes | virus |
T13 | 662-670 | SP_7 | denotes | COVID-19 |
T14 | 950-959 | GO:0005764 | denotes | lysosomal |
T15 | 1235-1242 | CHEBI:33695;CHEBI:33695 | denotes | message |
T14944 | 20-21 | GO:0000805 | denotes | X |
T12628 | 64-73 | GO:0005764 | denotes | lysosomal |
T151 | 254-261 | UBERON:0000948 | denotes | cardiac |
T63646 | 263-271 | UBERON:0001893 | denotes | cerebral |
T12987 | 276-281 | UBERON:0002113 | denotes | renal |
T76726 | 309-318 | UBERON:0002048 | denotes | pulmonary |
T80418 | 387-391 | UBERON:0002048 | denotes | lung |
T82531 | 450-461 | NCBITaxon:11118 | denotes | Coronavirus |
T86002 | 474-482 | SP_7 | denotes | COVID-19 |
T34415 | 499-509 | SP_7 | denotes | SARS-CoV-2 |
T95476 | 510-515 | NCBITaxon:10239 | denotes | virus |
T81259 | 662-670 | SP_7 | denotes | COVID-19 |
T77793 | 950-959 | GO:0005764 | denotes | lysosomal |
T91386 | 1235-1242 | CHEBI:33695;CHEBI:33695 | denotes | message |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
22 | 499-509 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
23 | 553-561 | Species | denotes | patients | Tax:9606 |
24 | 674-682 | Species | denotes | patients | Tax:9606 |
25 | 762-770 | Species | denotes | patients | Tax:9606 |
26 | 0-13 | Disease | denotes | Fabry disease | MESH:D000795 |
27 | 20-36 | Disease | denotes | X-linked disease | MESH:D040181 |
28 | 160-175 | Disease | denotes | acroparesthesia | MESH:D010292 |
29 | 177-205 | Disease | denotes | anhydrosis and angiokeratoma | MESH:D000794 |
30 | 276-295 | Disease | denotes | renal complications | MESH:D007674 |
31 | 309-330 | Disease | denotes | pulmonary involvement | MESH:D008171 |
32 | 387-399 | Disease | denotes | lung disease | MESH:D008171 |
33 | 422-448 | Disease | denotes | component of Fabry disease | MESH:D000795 |
34 | 450-472 | Disease | denotes | Coronavirus Disease-19 | MESH:C000657245 |
35 | 474-482 | Disease | denotes | COVID-19 | MESH:C000657245 |
36 | 567-580 | Disease | denotes | Fabry disease | MESH:D000795 |
37 | 662-670 | Disease | denotes | COVID-19 | MESH:C000657245 |
38 | 688-701 | Disease | denotes | Fabry disease | MESH:D000795 |
39 | 857-866 | Disease | denotes | infection | MESH:D007239 |
42 | 1373-1381 | Species | denotes | patients | Tax:9606 |
43 | 1387-1400 | Disease | denotes | Fabry disease | MESH:D000795 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 64-73 | Body_part | denotes | lysosomal | http://purl.org/sig/ont/fma/fma63836 |
T2 | 387-391 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
T3 | 950-959 | Body_part | denotes | lysosomal | http://purl.org/sig/ont/fma/fma63836 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 387-391 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T3 | 0-13 | Disease | denotes | Fabry disease | http://purl.obolibrary.org/obo/MONDO_0010526 |
T4 | 20-36 | Disease | denotes | X-linked disease | http://purl.obolibrary.org/obo/MONDO_0000425 |
T5 | 192-205 | Disease | denotes | angiokeratoma | http://purl.obolibrary.org/obo/MONDO_0003143 |
T6 | 375-399 | Disease | denotes | obstructive lung disease | http://purl.obolibrary.org/obo/MONDO_0002267 |
T7 | 387-399 | Disease | denotes | lung disease | http://purl.obolibrary.org/obo/MONDO_0005275 |
T8 | 435-448 | Disease | denotes | Fabry disease | http://purl.obolibrary.org/obo/MONDO_0010526 |
T9 | 474-482 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T10 | 499-507 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T11 | 567-580 | Disease | denotes | Fabry disease | http://purl.obolibrary.org/obo/MONDO_0010526 |
T12 | 662-670 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T13 | 688-701 | Disease | denotes | Fabry disease | http://purl.obolibrary.org/obo/MONDO_0010526 |
T14 | 857-866 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T15 | 950-976 | Disease | denotes | lysosomal storage diseases | http://purl.obolibrary.org/obo/MONDO_0002561 |
T16 | 1387-1400 | Disease | denotes | Fabry disease | http://purl.obolibrary.org/obo/MONDO_0010526 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 44-45 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T2 | 64-73 | http://purl.obolibrary.org/obo/GO_0005764 | denotes | lysosomal |
T3 | 101-102 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T4 | 146-151 | http://purl.obolibrary.org/obo/UBERON_0003101 | denotes | males |
T5 | 146-151 | http://www.ebi.ac.uk/efo/EFO_0000970 | denotes | males |
T6 | 387-391 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
T7 | 387-391 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
T8 | 510-515 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T9 | 520-527 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | labeled |
T10 | 531-532 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T11 | 950-959 | http://purl.obolibrary.org/obo/GO_0005764 | denotes | lysosomal |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T1 | 81-86 | Chemical | denotes | alpha | http://purl.obolibrary.org/obo/CHEBI_30216 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 160-175 | Phenotype | denotes | acroparesthesia | http://purl.obolibrary.org/obo/HP_0031006 |
T2 | 177-187 | Phenotype | denotes | anhydrosis | http://purl.obolibrary.org/obo/HP_0000970 |
T3 | 192-205 | Phenotype | denotes | angiokeratoma | http://purl.obolibrary.org/obo/HP_0001014 |
T4 | 375-399 | Phenotype | denotes | obstructive lung disease | http://purl.obolibrary.org/obo/HP_0006536 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 960-967 | http://purl.obolibrary.org/obo/GO_0051235 | denotes | storage |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T4 | 0-103 | Sentence | denotes | Fabry disease is an X-linked disease due to a deficiency of the lysosomal enzyme alpha-galactosidase A. |
T5 | 104-296 | Sentence | denotes | Clinical symptoms in classically affected males include acroparesthesia, anhydrosis and angiokeratoma, which may present during childhood followed by cardiac, cerebral and renal complications. |
T6 | 297-449 | Sentence | denotes | Even though pulmonary involvement is not widely appreciated by clinicians, an obstructive lung disease is another recognized component of Fabry disease. |
T7 | 450-647 | Sentence | denotes | Coronavirus Disease-19 (COVID-19), caused by the SARS-CoV-2 virus was labeled as a global pandemic and patients with Fabry disease can be considered at high risk of developing severe complications. |
T8 | 648-756 | Sentence | denotes | The impact of COVID-19 on patients with Fabry disease receiving enzyme replacement therapy is still unknown. |
T9 | 757-867 | Sentence | denotes | Many patients who receive treatment in the hospital experienced infusion disruptions due to fear of infection. |
T10 | 868-1089 | Sentence | denotes | Effects of temporary treatment interruption was described in more detail in other lysosomal storage diseases, but the recommencement of therapy does not fully reverse clinical decline due to the temporary discontinuation. |
T11 | 1090-1215 | Sentence | denotes | When possible, home-therapy seems to be the most efficient way to maintain enzyme replacement therapy access during pandemic. |
T12 | 1216-1243 | Sentence | denotes | Sentence take-home message: |
T13 | 1244-1401 | Sentence | denotes | Home-therapy, when possible, seems to be the most efficient way to maintain enzyme replacement therapy access during pandemic in patients with Fabry disease. |